SF
BMY.RT

Synovus Financial’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Synovus Financial’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,715
Closed -$5K – 809
2020
Q4 		$5K Sell
10,715
-3,633
-25% -$7.74K ﹤0.01% 756
2020
Q3 		$27K Sell
14,348
-571
-4% -$1.63K ﹤0.01% 701
2020
Q2 		$53K Sell
14,919
-1,094
-7% -$3.95K ﹤0.01% 891
2020
Q1 		$52K Buy
16,013
+1,375
+9% +$4.53K ﹤0.01% 1108
2019
Q4 		$35K Buy
+14,638
New +$38.1K ﹤0.01% 1014

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Synovus Financial's BMY.RT Position: Q1 2021 in Review

Synovus Financial sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 10,715 shares — an estimated $5K sold.

Synovus Financial first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $53K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Synovus Financial reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Synovus Financial sold 10,715 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $5K.
  • Synovus Financial first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Synovus Financial's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $53K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Synovus Financial's 13F filing for Q1 2021, filed 11 May 2021.